#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to understand that patients often pursue high-THC products based on misconceptions about potency, when cannabinoid profiles and terpene content more accurately predict therapeutic effects and adverse outcomes. Educating patients to ask budtenders about full product composition—similar to how clinicians review medication formulations—can improve treatment efficacy and reduce unwanted effects like anxiety or impaired cognition. This knowledge gap between provider recommendations and retail information creates an opportunity for clinicians to establish themselves as trusted sources on cannabis selection rather than defaulting to patient-driven retail choices.
Budtenders across multiple dispensaries emphasize that cannabis potency should not be the sole consideration when selecting products, as excessive focus on THC content may lead patients to overlook other cannabinoids and terpenes that meaningfully influence therapeutic effects and side effect profiles. The cannabinoid and terpene profile of a product, including CBD, CBN, and various terpenes like myrcene and limonene, collectively determine the clinical effects and patient experience more accurately than THC percentage alone. This perspective aligns with emerging pharmacological evidence suggesting that the entourage effect, wherein multiple cannabis compounds work synergistically, produces outcomes distinct from isolated high-THC formulations. Clinicians should educate patients that product selection based on comprehensive cannabinoid and terpene composition, rather than pursuing maximum THC levels, may improve therapeutic outcomes and reduce adverse effects such as anxiety or sedation. Patients seeking cannabis for specific medical conditions should work with informed dispensary staff to match product profiles to their individual needs and tolerance, similar to how conventional medications are dosed and selected based on mechanism of action rather than concentration alone.
“What budtenders are telling us aligns with clinical experience: THC potency is just one variable in a much more complex picture that includes cannabinoid ratios, terpene profiles, and individual patient factors. We still don’t have enough controlled research to say definitively how these compounds interact in most patients, but the evidence we do have suggests that chasing the highest THC number often misses the mark therapeutically.”
💚 While budtender recommendations reflect frontline retail experience rather than clinical evidence, their consistent advice to de-emphasize THC potency as the sole purchasing criterion aligns with emerging cannabinoid research suggesting that terpene profiles, CBD content, and product type significantly influence clinical effects and individual tolerability. The challenge for clinicians is that cannabis product labeling remains inconsistent across jurisdictions, cannabinoid ratios vary widely even within strain categories, and individual patient factors like prior cannabis exposure, underlying psychiatric conditions, and concurrent medications create substantial heterogeneity in response. When counseling patients who choose to use cannabis, particularly those with anxiety, psychosis risk, or substance use history, practitioners should encourage attention to full product composition beyond THC percentage and advocate for patients to start with lower doses in controlled settings, though rigorous clinical trials comparing different cannabinoid ratios remain limited. This gap between retail knowledge and clinical evidence underscores the need for better
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
